Current challenges with supply-chain integrity and the threat to the quality of marketed drugs

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 2, 2011, Pages 316-319

  Paxton, M ^a  

^a Pharmaceutical Research and Manufacturers of America   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR;

ARTICLE; AWARENESS; DRUG MANUFACTURE; DRUG MARKETING; DRUG PACKAGING; DRUG QUALITY; FOOD AND DRUG ADMINISTRATION; GOOD MANUFACTURING PRACTICE; INTERNET; PRESCRIPTION; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

DRUG INDUSTRY; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WORLD HEALTH ORGANIZATION;

EID: 78951494829     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.288     Document Type: Article

References (6)

1. Pharmaceutical Security Institute. Incident trends http://www.psi-inc. org/incidentTrends.cfm http://www.psi-inc.org/incidentTrends.cfm (2010).
2. US food and Drug administration. fDa Warns about fraudulent Tamiflu http://www.fda.gov/NewsEvents/Newsroom/Pressannouncements/ucm216148.htm (2010).
3. US food and Drug administration. Cargo thefts http://www.fda.gov/ICECI/ CriminalInvestigations/ucm182888.htm (2010).
4. DiMasi, J.A. & Grabowski, H.G. The cost of biopharmaceutical R&D: is biotech different? Manag. Decis. Econ. 28, 469-479 (2007).
5. World Health Organization. Proposal for revision of WHO good distribution practices for pharmaceutical products http://www.who.int/medicines/services/ expertcommittees/pharmprep/170909Clean-GDP-counterfeits- QaS08252Rev1.pdf (September 2009).
6. RxUSa Wholesale, Inc. v. Department of Health and Human Services, No. 06- CV-5086 (E.D.N.Y., 8 December 2006).